Precision Diabetology Validated: Algorithm for SGLT2i and DPP4i Selection Performs Accurately Across Major UK Ethnicity Groups

MedXY Editorial Team•Dec 19, 2025•Diabetes & Endocrinology

External validation confirms that a clinical algorithm for selecting between SGLT2 inhibitors (SGLT2i) and DPP4 inhibitors (DPP4i) is accurate across White, Black, South Asian, and Mixed/Other ethnicity groups in the UK.
While SGLT2i predictions were robust across groups, minor recalibration was required for DPP4i predictions due to higher-than-expected observed glycemic responses.
The predicted glycemic advantage of SGLT2i over DPP4i was most pronounced in individuals of White ethnicity (3.7 mmol/mol) compared to South Asian (2.1 mmol/mol) and Black (0.6 mmol/mol) groups.
Results support the clinical utility of the MASTERMIND selection model as a tool for personalized diabetes management in multi-ethnic populations.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

External validation confirms that a clinical algorithm for selecting between SGLT2 inhibitors (SGLT2i) and DPP4 inhibitors (DPP4i) is accurate across White, Black, South Asian, and Mixed/Other ethnicity groups in the UK.
While SGLT2i predictions were robust across groups, minor recalibration was required for DPP4i predictions due to higher-than-expected observed glycemic responses.
The predicted glycemic advantage of SGLT2i over DPP4i was most pronounced in individuals of White ethnicity (3.7 mmol/mol) compared to South Asian (2.1 mmol/mol) and Black (0.6 mmol/mol) groups.
Results support the clinical utility of the MASTERMIND selection model as a tool for personalized diabetes management in multi-ethnic populations.